The House is expected to begin a final vote Nov. 12 on the Senate-backed funding package, bringing a potential end to the government shutdown one step closer.
The AHA announced Nov. 12 that Pete November, president and CEO of Ochsner Health in Louisiana, will fill a vacancy on its Board of Trustees effective Jan. 1, 2026, through Dec. 31, 2028.
Vickie Johnson, executive vice president and chief community officer at Cleveland Clinic, and Roopa Thakur, M.D., pediatrician and associate program director of the Pediatric Residency Program at Cleveland Clinic Children’s, share how community collaboration, education and home remediation are driving Cleveland Clinic’s ambitious plan to ensure that every home and childcare center is lead-safe.
The AHA will host the third session of its virtual webinar series on workforce development Nov. 19 at 12:30 p.m. ET. This session will explore how centralized, data-driven strategies can empower nursing leaders to optimize workforce development and drive success.
A blog by Michelle Schweitzer, executive director of advanced practice providers at WakeMed Health and Hospitals, and Dawn Mutchko, principal consultant at AdVantage Advanced Practice Consulting, explains how the Advanced Practice Providers Leadership Advisory Group created the APP Leadership Structure Principles to help hospitals and health systems support the increasing contributions of APPs in care delivery.
The Senate Nov. 10 passed legislation to fund the federal government that will now head to the House for a vote as early as the evening of Nov. 12, as an end to the record-long government shutdown appears to be close.
Elizabeth Dabrowski, M.D., pediatric endocrinologist at Children’s Wisconsin, and Matthew Edwards, R.D., diabetes care and education specialist at Children’s Wisconsin Diabetes Prevention Clinic, share how a collaborative approach — including endocrinologists, dietitians and physical therapists — empowers families to make sustainable lifestyle changes.
AHA leaders tomorrow will participate in a series of panels during the International Hospital Federation’s 48th annual World Hospital Congress in Geneva.
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to advance a government funding agreement.
by Tina Freese Decker, Chair, American Hospital Association
For more than 30 years, thanks to bipartisan congressional support, the 340B program has helped eligible hospitals stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the communities they serve.
Senate negotiations on a potential funding deal to end the record-long government shutdown are ongoing, and the chamber is likely to continue working through this weekend in hopes of nearing a resolution.
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned with those paid in other countries, known as most-favored-nation pricing.
The AHA Nov. 7 released “Integrating Behavioral Health into Pediatric Care: Hospital-led Solutions to a Growing Crisis,” featuring five case studies on how the integration of behavioral health care into a variety of care settings means clinicians can recognize symptoms early, provide immediate support and reduce the chance of escalation into emergencies or long-term treatment.
The AHA will host a webinar Nov. 13 at 2 p.m. ET that will explore scalable, community-driven strategies that support patients and improve outcomes during the vital transition period from hospital to home.
Caitlin Gillooley, AHA director of quality and behavioral health policy, and Evelyn Ivy Mwangi, M.D., Luminis Health Anne Arundel Medical Center geriatric hospitalist, will discuss the Centers for Medicare & Medicaid Services’ Age-Friendly Hospital Measure and Luminis Health’s success in meeting it during a webinar Nov. 20 at noon ET.
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed nations, known as the most-favored-nation price.